Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

Christopher Bunick, MD, PhD

Associate Professor, Dermatologist

Yale University

Middlebury, Connecticut

Ruth Ann Vleugels, MD, MPD, MBA

Vice-Chair of Academic Affairs

Department of Dermatology at Brigham and Women’s Hospital

Boston, Massachusetts

Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

Segment Description: Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.